**A customizable multiplex protein microarray for antibody testing and its application**

**for tick-borne and other infectious diseases.**

Hari Krishnan Krishnamurthy[1]*, Vasanth Jayaraman[1], Karthik Krishna[1], Tianhao Wang[1],

Kang Bei[1], Chithra Suresh[2], Shiny Matilda[2], Alex J Rai[3], Renata Welc-Falęciak[4], Agnieszka

Pawełczyk[5], Lucas S. Blanton[6], Aleš Chrdle[7], Andrea Fořtová[8], Daniel Růžek[9], Gheyath K.

Nasrallah[10], Laith J. Abu-Raddadi[10], Duaa W. Al-Sadeq[10], Marah Abed Alhakim Abdallah[10],

Daniele Lilleri[11], Chiara Fornara[11], Piera D'Angelo[11], Milena Furione[11], Maria Söderlund-

Venermo[12], Klaus Hedman[12], Dimosthenis Chochlakis[13], Anna Psaroulaki[13], Eirini

Makridaki[13], Artemis Ntoula[13], John J. Rajasekaran[1].

1 Vibrant Sciences LLC., San Carlos, CA, United States of America

2 Vibrant America LLC., San Carlos, CA, United States of America

3 Columbia University, Irving Medical Center, Dept. of Pathology & Cell Biology

4 Department of Parasitology, Faculty of Biology, University of Warsaw, Diagnostic

Laboratory of Parasitic Diseases and Zoonotic Infections, Biological and Chemical Research

Centre, Warsaw, Poland.

5 Department of Immunopathology of Infectious and Parasitic Diseases, Medical University

of Warsaw, 3C Pawińskiego Street, 02-106, Warsaw, Poland

6 Department of Internal Medicine, Division of Infectious Diseases, University of Texas

Medical Branch, Galveston, TX 77555, USA.

7 Department of Infectious Diseases, Hospital Ceske Budejovice, Ceske Budejovice, Czech

Republic; Royal Liverpool University Hospital, Prescot St, Liverpool L7 8XP, UK.

8 Veterinary Research Institute, Brno, Czech Republic; Faculty of Science, Masaryk

University, Brno, Czech Republic

9 Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske

Budejovice, Czech Republic; Veterinary Research Institute, Brno, Czech Republic, Faculty of

Science, Masaryk University, Brno, Czech Republic.

10 Biomedical Sciences Department, College of Health Sciences, Qatar University, Doha

P.O. Box 2713, Qatar.

11 Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.

12 Virology, University of Helsinki, Haartmaninkatu 3, FI-00290, Helsinki, Finland.

13 Laboratory of Clinical Microbiology and Microbial Pathogenesis, School of Medicine,

University of Crete, PC 70013, Heraklion – Crete – Greece.

Corresponding Author: * hari@vibrantsci.com (HKK)

Vasanth Jayaraman: vasanth.jayaraman@vibrantsci.com

Karthik Krishna: karthik@vibrantsci.com

Tianhao Wang: tianhao.wang@vibrantsci.com

Kang Bei: kang@vibrantsci.com

Chithra Suresh: chithra.s@vitasoft-tech.com

Shiny Matilda: shiny.m@vitasoft-tech.com

Alex J Rai: ajr2170@cumc.columbia.edu

Renata Welc-Falęciak: rwelc@biol.uw.edu.pl

Agnieszka Pawełczyk: agnieszka.pawelczyk@wum.edu.pl

Lucas Blanton: lsblanto@utmb.edu

Aleš Chrdle: chrdle.ales@nemcb.cz

Andrea Fořtová: fortova@vri.cz

Daniel Růžek: ruzekd@paru.cas.cz

Gheyath K. Nasrallah: gheyath.nasarallah@qu.edu.qa

Laith J. Abu-Raddadi: lja2002@qatar-med.cornell.edu

Duaa W. Al-Sadeq: da1206066@student.qu.edu.qa

Marah Abed Alhakim Abdallah: marah.hakim3@gmail.com

Daniele Lilleri: d.lilleri@smatteo.pv.it

Chiara Fornara: c.fornara@smatteo.pv.it

Piera D'Angelo: p.dangelo@smatteo.pv.it

Milena Furione: m.furione@smatteo.pv.it

Maria Söderlund-Venermo: maria.soderlund-venermo@helsinki.fi

Klaus Hedman: klaus.hedman@helsinki.fi

Dimosthenis Chochlakis: surreydimos@hotmail.com

Anna Psaroulaki: psaroulaki@uoc.gr

Eirini Makridaki: rmakridaki@yahoo.gr

Artemis Ntoula: artemisntoula@gmail.com

John J. Rajasekaran: jjrajasekaran@vibrantsci.com

**Abstract**

Tick-borne infections are the most common vector-borne diseases in the USA. Ticks harbor and spread several infections with Lyme disease being the most common tickborne infection in the US and Europe. Lack of awareness about tick populations, specific diagnostic tests, and overlapping symptoms of tick-borne infections can often lead to misdiagnosis affecting treatment and the prevalence data reported especially for non-Lyme tick-borne infections. The diagnostic tests currently available for tick-borne diseases are severely limited in their ability to provide accurate results and cannot detect multiple pathogens in a single run. The multiplex protein microarray developed at Vibrant was designed to detect multiple serological antibodies thereby detecting exposure to multiple pathogens simultaneously. Our microarray in its present form can accommodate 400 antigens and can multiplex across antigen types, whole cell sonicates, recombinant proteins, and peptides. A designed array containing multiple antigens of several microbes including *Borrelia burgdorferi,* the Lyme disease spirochete, was manufactured and evaluated. The immunoglobulin M (IgM) and G (IgG) responses against several tick-borne microbes and other infectious agents were analyzed for analytical and clinical performance. The microarray improved IgM and IgG sensitivities and specificities of individual microbes when compared with the respective gold standards. The testing was also performed in a single run in comparison to multiple runs needed for comparable testing standards. In summary, our study presents a flexible multiplex microarray platform that can provide quick results with high sensitivity and specificity for evaluating exposure to varied infectious agents especially tick-borne infections.

Keywords: Tick-borne infections, Lyme disease, multiplex, microarray, immunoglobulin, tick bite, co-infections, infectious disease.

**Introduction**

Most vector-borne infections in the USA can be attributed to pathogens transmitted via tick bites. Of all tick-borne infections identified to date, Lyme disease is the most prevalent infection [1]. Lyme disease is a potentially serious bacterial infection transmitted by ticks and was first reported in the mid-1970s in the USA. The etiological agent was identified later as *Borrelia burgdorferi* [2,3,4]. Several studies have reported the presence of co-infections along with Lyme disease [5] including *Babesia spp.* [6]*, Bartonella spp.* [7]*, Ehrlichia spp.* [8]*, Anaplasma phagocytophilum* [8]*,* Powassan Virus [9], *Toxoplasma gondii* [10]*, Rickettsia spp.* [11]*,* tick-borne encephalitis virus [12], and West Nile virus [13]. Additionally, prolonged exposure to Lyme and other tick-borne infections could potentially weaken the patient's immune system increasing the risk of infections like Epstein Barr virus [14], cytomegalovirus [14], parvovirus B19 [5], coxsackie virus [15], HSV-1 [16], HSV-2 [16], and HHV-6 [14].

Ticks have been shown to transmit more than one infectious agent in a single bite. For instance, a study by Wormser et al. showed that there was a chance of getting infected with *A. phagocytophilum* (30%) and *B. microti* (24%) along with Lyme disease [17]. Currently, multi-tiered testing is carried out for diagnosing tick-borne infections [18] (https://tinyurl.com/yeyxevve). In this method, the infectious agents are tested sequentially, starting with Lyme disease. This method is time-consuming and can often lead to delayed diagnosis, accompanied with high cost to the patient [18, 19] (https://tinyurl.com/yeyxevve). Testing for multiple infections in a single run can help physicians arrive at an accurate diagnosis especially since Lyme disease shares symptoms with other vector-borne co-infections [20]. The existing diagnostic assays possess various limitations that restrict their applicability in the diagnosis of these infections. The diagnosis of Lyme disease and other

infections using several blot-based and single-plex ELISA tests remain rudimentary in terms

of arriving at a diagnostic conclusion [21]. Additionally, blot-based assays may have

overlapping proteins with similar mass requiring additional testing to tease out the specific

antigen to which the antibody is bound. A multiplex system can detect the biomarkers of

Lyme disease, potential co-infections, and other infections in a single run. A serology-based

multiplexing system may be preferred to a PCR multiplex system mainly due to its

accessibility, for instance using dried blood spots [22]. Additionally, serology overcomes the

issue of low availability of genetic material due to the transient nature of some of these

organisms [23]. A serological-based system is also ideal for population screening and

surveillance since it can indicate past exposure to a pathogen.

Our customisable protein microarray design includes antigens physically separated by design

unlike blot assays and can multiplex across species. Multiplexing can also be done across

antigen types such as recombinant proteins, peptides, and lysates simultaneously. This

method can lower test costs since all the manufacturing is automated using bio customised

semiconductor processes similar to how electronic chips are made. The multiplex microarray

has three main advantages over the existing technologies. It has an ultra-high-density array

surface with high reproducibility and better throughput. It can detect a large number of

antibodies against varied infectious agents at the same time. Detection of antibodies can be

performed using low sample volumes with low cost and a fast turnaround time [21]. Given

the flexible nature of the multiplex platform, we aimed to provide a multiplexed testing

solution for Lyme, its co-infections, and other possible infections of interest.

**Materials and Methods**

**Patients Sera**

The sera from 2990 individuals were collected after seeking appropriate Institutional Review

Board (IRB) approval under respective collaborators (Supplementary Table 6). Table 1 lists

the provided samples for Lyme disease, co-infections, and other infections along with the

counts, respective collaborators and methods used to ascertain the clinical diagnosis by the

physician. These reference sera were tested at Vibrant America Clinical Labs (CLIA and

CAP accredited facility) by laboratory personnel in a blinded manner. The sera from healthy

patients were considered negative and were used to set the cut-off values and were

investigated under IRB exemption (work order #1-1574995-1) determined by the Western

Institutional Review Board (WIRB) to employ de-linked and de-identified human specimens

and medical data for research findings. The negative sera were collected from across the US

including endemic and nonendemic regions for these infections.

**Processing of Wafers**

Wafers were functionalized as described previously [21,24] (https://tinyurl.com/mr9ctppy).

Briefly, silicon wafers were exposed to an environment of pure oxygen for 2h followed by

washing (deionized Water) and coating (1% (vol/vol) with 3-aminopropyltriethoxysilane

(APTES) in N-methylpyrrolidone (NMP). Curing was carried out at 120 °C for 60 minutes

under an N2 atmosphere and humidity-controlled environment. Coating and incubation of the

wafer with a co-polymer solution of poly (L-lysine) and poly (lactic acid) for 24h were

carried out to increase the binding efficiency of the surface on to which the antigens were

immobilized via passive adsorption/hydrophobic interactions with the copolymers [Figure

1].

**Immobilization of Antigens**

The antigens included in the assay are listed in Table 2. Pathogens transmitted by ticks and

their respective antigens for potential future additions are listed in Figure 2 [25-30]

(https://tinyurl.com/37dprsy7). The recombinant antigens were expressed in *E. coli* bacteria

using full-length cDNA coding for the respective antigens fused with a hexa histidine

purification tag. The whole cell sonicate was obtained from organisms cultured according to

ATCC protocols prior to lysing them which yielded a cocktail of the cell membrane, cell

wall, and cytosolic proteins. Peptide antigens were synthesized by photolithography as shown

in our previous publications [31,32]. The capture antigens including the recombinant antigens

that mimic the natural pathogen and the whole-cell sonicate were incubated on the wafer at a

concentration of 1.0 µg/ml and reacted for 24h at 4 °C. The unbound antigens were removed

by washing with aqueous phosphate buffer and the unreacted substrate was quenched with a

blocking solution containing BSA and glycine. The immobilized antigens were classified

with unique identifiers assigned to each wafer. In this study, we employed the microarray to

detect Lyme disease, co-infections, and other agents of interest including, *B. microti, B.*

*henselae, A. phagocytophilum, E. chaffeensis, R. typhi,* Powassan virus , tick-borne

encephalitis virus, West Nile virus, coxsackie virus, cytomegalovirus, Epstein Barr virus,

parvovirus B19, *T. gondii,* HSV-1, HSV-2, and HHV-6 [Figure 2].

**Pillar Plate Assembly**

Individual wafers were stealth diced into 0.70 x 0.70mm$^2$ microchips for each antigen. A

standard die-sorting system was used to pick and place these wafers onto individual carrier

tapes. The carrier tapes were then placed onto a high-throughput surface mount technology

(SMT) component placement system. Finally, microchips were mounted onto 24 pillar plates

and each pillar contains 87 microchips with each chip designated for one antigen –

recombinant protein, peptide or whole cell sonicates [Figure 1].

**Immunochip assay and Antibody detection**

Serum samples were probed using 1:20 dilution on the pillar plate and incubated for 1h at room temperature followed by alternate washing and incubation as described previously [21]. The plate was then incubated for an hour with the secondary antibody (1:2000 dilution of Goat Anti-Human IgG HRP and Goat Anti-Human IgM HRP individually) and washed with TBST buffer followed by DI Water. The plates were left for drying preceding the addition of chemiluminescent substrate and the performance of chemiluminescent imaging. An enhanced IgM sensitivity was achieved by pre-reacting the sera with proprietary assay components leading to IgG stripping prior to IgM testing.

The detection of multiplex antibodies is based on the chemiluminescent immunoassay and can be performed using <200 μL of serum. Sample dilution, multi-step incubation, and multi-solution washing are programmed into liquid handlers. The immunochip has the capacity to assay 192 individual specimens in 2h. Raw chemiluminescent signals for each probe are extracted and converted into intensity plots by an in-house reporter software. This method of automatic antigen detection can dramatically shorten the turnaround time, reduce the cost of labor and instrument, and eliminate the need for manual handling and subjective interpretation of the WB or IB test results when compared to the traditional two-tiered testing recommended by the CDC. All the antibodies are detected in a single run.

**Data analysis**

An in-house software extracts the chemiluminescent signals from the generated images which were converted to intensity plots. The average intensity of each antibody was compared with the cut-off values assigned for each antigen to track seropositivity.

## Results

### Custom Protein Microarray Platform

The main components of the Immunochip platform include multiple silicon-based $0.70 \times$

$0.70$ mm$^2$ microchips that are laser diced from antigen-immobilized wafers, a customized 24

well compatible plate containing 24 pillars, each containing 87 microchips that are picked

and placed into a multiplex microarray assembly, and a high-resolution imager capable of

simultaneously detecting chemiluminescent signals from labelled antigen–antibody reactions

at each microchip throughout the multiplex microarray (Figure 1). Each chip can be

considered analogous to an individual band in a Western blot; however, the proteins are

physically separated eliminating cross-reactive issues usually seen in blot-based assays for

proteins with similar mass. Figure 1 provides an overview of the microarray manufacturing

process. Figure 2 shows the individual chips that are placed in each pillar, a single serum

sample will be applied to each pillar thereby assaying the antibodies in serum against all

antigens at the same time.

### Analysis of serological response

The Vibrant tick-borne disease panel tests for IgG and IgM antibodies for Lyme disease and

other infectious agents as mentioned in Table 2 and Figure 2. The IgM and IgG immune

responses were analysed, and the clinical sensitivities and specificities were tabulated in

Table 3. The samples reacted with a specific immunoreactive epitope of the 87 different

antigens that were being tested. The immunoreactivity of these antigens was contrasted with

that of the controls.

**Enhanced IgM Assay**

IgM antibodies are the primary antibodies produced by the immune system during infections,
but they make up only 5% to 10% of all the circulating antibodies [33]. An in-house IgM
assay was developed to remove most IgG antibodies and other non-specific proteins from the
serum prior to the IgM immunoassay. This helped to increase the sensitivity and specificity
of the assay. Human IgG was removed by incubating the serum with a purified goat anti-
human (GAH) IgG Fc fragment and proprietary assay reagents.

**Analytical Performance**

The analytical performance of the immunochip was evaluated for precision
(repeatability/reproducibility), analytical sensitivity, reportable range, linearity, and matrix
equivalency studies. Samples for negatives, low or moderate positives, and high positives
were run with duplication to determine the analytical performance metrics.  The precision
study used a panel of 11 samples and was run over a period of 20 days with 2 duplicates per
run and 4 runs per day. The results are tabulated as shown in Supplementary Table 1. Lot to
Lot reproducibility was also tested to check for variation in the manufacturing of the pillar
plates by running a panel of 11 samples with 5 replicates per run, 3 runs per day over a period
of 5 days using 3 manufactured lots. The results are tabulated as shown in Supplementary
Table 2. Testing of protein-free serum matrix samples and low antibody concentration
samples with 2 replicates per run, 2 runs per day over a period of three days was used to
determine analytical sensitivity. The limit of blank (LoB) and limit of quantitation (LoQ) was
calculated using the mean and standard deviation of the blank and the low antibody
concentration samples as shown in Supplementary Table 3. The linearity and reportable range
were verified by running samples with varying levels of antibodies and checking assay

recovery, the results are tabulated in Supplementary Table 4. Matrix equivalence studies are

shown in Supplementary Table 5. The potential interference of specific endogenous and

exogenous substances with the immunochip was evaluated by performing an interfering

substance study. The interfering substances tested were 60 mg/dl bilirubin, 100 mg/ml

cholesterol, 1000 mg/ml triglycerides, 1000 mg/ml hemoglobin, and 6 g/dl albumin. There

was no interference between the immunochip and the substances tested at the mentioned

levels.

**Clinical Sensitivity and Specificity**

Table 3 provides an overview of the IgG and IgM sensitivities measured by the Vibrant

microarray. This is compared with the sensitivities and specificities of the current gold

standard tests for the particular pathogen. The Vibrant microarray was able to achieve high

sensitivities and specificities when compared with the gold standards for each

pathogen. Supplementary Table 7 provides more details on the gold standard diagnostic tests

for the pathogens along with the modes of transmission and their endemic regions.

**Evaluating the antigens of *Borrelia burgdorferi***

In this study, individual antigens of *B. burgdorferi* were tested for reactivity with IgG and

IgM antibodies (Table 4). The heat map (Figure 3) shows the performance metrics of the

different antigens. Testing for Lyme disease since 1994 has been based on conventional two-

tiered testing (CTTT) where an enzyme immunoassay (EIA) is followed by a specific

immunoblot for a definitive diagnosis. Recently, CTTT has been replaced with a modified

two-tier testing (MTTT) in which an EIA using whole cell sonicate is followed by an EIA

using C6 peptide. This shows the increasing shift away from blot-based testing to

conventional ELISA. MTTT removes the burden of immunoblots which are tedious to run,

more expensive and could have subjective interpretation of bands [49]. Complete

replacement of immunoblots can be done using a microarray platform such as the one

described here. The full data set would be available to the physicians to make a nuanced

diagnosis instead of a narrow subset of antigens run on ELISAs.

**Discussion**

Ticks are among the most important sources of vector-borne infections in the US [50]. The

spread of ticks across the US has been steadily increasing over the past decades. In parallel,

the discovery of novel pathogens that are spread by ticks has also seen dramatic increases

[51]. Currently, there are 11 major tickborne diseases according to the CDC namely, Lyme

disease, babesiosis, ehrlichiosis, Rocky Mountain spotted fever, Southern tick-associated rash

illness, tick-borne relapsing fever, tularemia, anaplasmosis, Colorado tick fever, and

Powassan encephalitis [52] (https://www.cdc.gov/ticks/diseases/index.html). Patients are

rarely tested for all possible infections that could be transmitted via a tick bite [53]. The

current diagnostic tests are severely limited in distinguishing various tick-borne infections

and several studies have revealed that non-Lyme tick-borne infections are heavily

underdiagnosed [54].

Among varied testing options PCR and serology-based assays are reliable and most widely

used. PCR has several advantages as it detects pathogenic DNA/RNA which conclusively

proves the organism's presence. It has high specificity and has a high throughput with assay

run times of about 2 hours. It can also detect the infection during its early stages [55]. There

are however certain drawbacks to testing using PCR, especially with tickborne infections.

Pathogens transmitted by ticks may be transient in the blood resulting in false negative PCR

results in tick-borne diseases, namely, *B. burgdorferi, R. typhi, T. gondii*, HSV-1, EBV,

TBEV, and WNV [23]. PCR testing requires specialised laboratories and equipment for

testing. PCR may not detect all strains and variants and is limited to detecting known

pathogens [56]. Multiplexing using PCR is limited due to fixed number of analytes that can

be parallelly read using PCR instrumentation.

Serology-based testing has several advantages when it comes to tick-borne infection testing.

It has the ability to comprehensively assess immune responses and simultaneously detect

exposure to multiple pathogens including previous and unresolved infections. Testing two

times with a time interval in between can also help diagnose active infections based on

altered serum antibody profiles. Simultaneous detection of antibodies against multiple tick-

borne pathogens using a single sample and providing a comprehensive view of the patient's

immune response is a key advantage of serology-based multiplex testing [23]. The testing can

also be done in resource poor settings with collection using a dried blood spot [22].

Serological testing can diagnose tick-borne diseases even in the later stages when pathogen

detection through molecular methods becomes more challenging [23,57]. It also reduces the

risk of false negatives [57]. Serological multiplex testing being cost-effective can also

contribute to surveillance and epidemiological studies by providing valuable data on the

prevalence and distribution of tick-borne diseases, enhancing our understanding of disease

dynamics [58]. However, serological studies have their own limitations. Serological testing

may not be able to detect early/recent infections. It relies heavily on the timing of sample

collection and the host's immune responses. In certain cases, molecular testing may be needed

to confirm serological testing [23]. Despite all this, the benefits of serology testing outweigh

its limitations which is why it is recommended by the CDC as the standard of testing for

Lyme disease.

Apart from PCR and ELISA serology tests, IFA and culture methods have also been suggested for diagnosing tick-borne infections. Testing using IFA is limited due to a lack of standardized antigenic targets, the subjective establishment of positive thresholds, and cross reactivity. These factors can result in varying accuracy of IFA results across laboratories [23]. Furthermore, Bacterial or viral cultures are not recommended for the diagnosis of tick-borne infections. This is due to the time-consuming nature of the test, the need for special media, and procedures that are only performed at specific laboratories [61].

This study employed a serology-based microarray developed at Vibrant to multiplex Lyme and other tick-borne infections along with a few other infections of interest. The uniqueness of the microarray lies in the application of the immunodominant antigens that eliminate nonspecific binding with high sensitivity needed for accurate diagnosis. Antigens could be evaluated in a multiplex setting to gauge their performance with clinical samples to pick the ideal set of antigens for any infection. To the best of our knowledge, this is the first report on the broad panel of antigens for Lyme disease and its co-infection testing in such a flexible format. The structure of the Vibrant pillar plate is designed to encompass 400 probe chips at each pillar facilitating the detection of an array of co-infections in a single run, saving cost, labor, and time. Further compaction of the chip allows improved performance by enhancing multiplexing and widening its clinical applications. The microarray platform is advantageous over other existing gold standards for tick-borne diseases and was able to overcome several of their limitations. Average time for multitier testing for several tickborne pathogens could take several months whereas the microarray technology takes only about a day to perform [21]. The microarray detected 17 tick-borne and other infections along with Lyme disease with sensitivities and specificities listed in Table 3.

In conclusion, the protein microarray with a multiplex of antigens was validated for Lyme
and its co-infections. The impact of simultaneous testing of co-infections leads to focused and
efficacious therapeutic recommendations. This approach caters to the diagnostic needs of
patients owing to its high sensitivity and specificity, affordable cost, quick availability of
results, and low sample volume requirement. Measures for syndromic surveillance,
diagnostic preparedness in disease outbreak investigations, personal protection, and education
of clinical health professionals and patients could pave the way for controlling tick-borne
infections better. As the known repertoire of antigens increases, this flexible microarray
format can be customised to include these new antigens. Future editions could also include
other infections/agents namely Colorado tick fever, heartland virus, rickettsiosis, Rocky
Mountain spotted fever, Southern tick-associated rash illness, tick-borne relapsing fever, and
tularemia which can be tested in parallel. Novel antigens for pathogens which may include
whole cell sonicates, recombinant proteins or peptide epitopes can be added as the science
progresses leading to continuous improvement in diagnostic technology for detecting tick-
borne infections.

Declarations:

Author Contributions

Conception and study design: HKK, JJR, VJ. Performing experiments: KK, TW. Analysis
and interpretation: KB, KK. Writing-original draft: HKK, CS, SM. Review and editing:
HKK, CS, AJR, RWF, AP, LSB, AC, AF, DR, GKN, LJA, DWA, MAA, DL, CF, PD, MF,
MSV, KH, DC, AP, EM, and AN. Sample resources: RWF, AP, LSB, AC, AF, DR, GKN,
LJA, DWA, MAA, DL, CF, PD, MF, MSV, KH, DC, AP, EM, and AN. All authors
reviewed and approved the final manuscript.

Competing interests

The authors have read the journal's policy and the authors of this manuscript have the

following competing interests: CS and SM are paid employees of Vibrant America LLC. KK,

VJ, TW, KB, HKK, and JJR are paid employees of Vibrant Sciences LLC. The other authors

are academic collaborators who provided samples and assisted in the review and editing of

the manuscript. AJR is a paid consultant of Vibrant America LLC. Vibrant America offers

commercial testing for Lyme disease and other infectious diseases and could benefit from

increased testing.

Funding

Vibrant America provided funding for this study in the form of salaries for authors [CS, SM,

KK, VJ, TW, KB, HKK, JJR]. The funders had no role in study design, data collection,

analysis, decision to publish, or preparation of the manuscript.

Acknowledgment

Vibrant Sciences LLC developed the microarray technology showcased in the publication.

All IP associated with the microarray manufacture and diagnostics belongs to Vibrant

Sciences. The specific roles of authors are stated in the author contribution section.

Availability of Data

The data used to support the findings of this study can be acquired from Vibrant America

LLC.

References

1.  Rochlin, I., & Toledo, A. (2020). Emerging tick-borne pathogens of public health
importance: a mini-review. *J Med Microbiol*, *69*(6), 781–791.

2. Burgdorfer, W., Barbour, A. G., Hayes, S. F., Benach, J. L., Grunwaldt, E., & Davis, J. P. (1982). Lyme disease—a tick-borne spirochetosis?. *Science*, *216*(4552), 1317-1319.

3. Johnson, R. C., Schmid, G. P., Hyde, F. W., Steigerwalt, A. G., & Brenner, D. J. (1984). Borrelia burgdorferi sp. nov.: etiologic agent of Lyme disease. *International Journal of Systematic and Evolutionary Microbiology*, *34*(4), 496-497.

4. Steere, A. C., Strle, F., Wormser, G. P., Hu, L. T., Branda, J. A., Hovius, J. W., ... & Mead, P. S. (2016). Lyme borreliosis. *Nature reviews Disease primers*, *2*(1), 1-19.

5. Berghoff, W. (2012). Chronic Lyme Disease and Co-infections: Differential Diagnosis. *Open Neurol J*, *6*(Suppl 1), 158–178.

6. Knapp, K. L., & Rice, N. A. (2015). Human Coinfection with Borrelia burgdorferi and Babesia microti in the United States. *J Parasitol Res*, *16*(3), 385–391.

7. Angelakis, E., Billeter, S. A., Breitschwerdt, E. B., Chomel, B. B., & Raoult, D. (2010). Potential for Tick-borne Bartonelloses. Emerg Infect Dis, 16(3), 385–391.

8. Ismail, N., Bloch, K. C., & McBride, J. W. (2010). Human Ehrlichiosis and Anaplasmosis. *Clin Lab Med*, *30*(1), 261–292.

9. Hart, C. E., Middleton, F. A., & Thangamani, S. (2022). Infection with Borrelia burgdorferi Increases the Replication and Dissemination of Coinfecting Powassan Virus in Ixodes scapularis Ticks. *Viruses*, *14*(7), 1584.

10. Ben-Harari, R. R. (2019). Tick transmission of toxoplasmosis. *Expert Review of Anti-infective Therapy*, *17*(11), 911-917.

11. Koetsveld, J., Tijsse-Klasen, E., Herremans, T., Hovius, J. W. R., & Sprong, H. (2016). Serological and molecular evidence for spotted fever group Rickettsia and Borrelia burgdorferi sensu lato co-infections in The Netherlands. *Ticks Tick Borne Dis*, *7*(2), 371-7.

12. Gustafson, R., Svenungsson, B., Gardulf, A., Stiernstedt, G., & Forsgren, M. (1990). Prevalence of tick-borne encephalitis and Lyme borreliosis in a defined Swedish population. *Scand J Infect Dis*, *22*(3), 297-306.

13. Lawrie, C. H., Uzcátegui, N. Y., Gould, E. A., & Nuttall, P. A. (2004). Ixodid and argasid tick species and West Nile virus.

14. Smith, A., Oertle, J., Warren, D., & Prato, D. (2015). Chronic Lyme Disease Complex and Its Commonly Undiagnosed Primary and Secondary Co-Infections. *Open Journal of Medical Microbiology*, *5*(3).

15. Freundt, E. C., Beatty, D. C., Stegall-Faulk, T., & Wright, S. M. (2005). Possible Tick-Borne Human Enterovirus Resulting in Aseptic Meningitis. *J Clin Microbiol*, *43*(7), 3471–3473.

16. Gylfe, A., Wahlgren, M., Fahlén, L., & Bergström, S. (2002). Activation of latent Lyme borreliosis concurrent with a herpes simplex virus type 1 infection. *Scand J Infect Dis*, *34*(12), 922-4.

17. Wormser, G. P., McKenna, D., Scavarda, C., Cooper, D., El Khoury, M. Y., Nowakowski, J., ... & Wong, S. J. (2019). Co-infections in persons with early Lyme disease, New York, USA. *Emerging infectious diseases*, *25*(4), 748.

18. Quest diagnostics. (2018). *Tick-borne Diseases*. Quest Diagnostics.

19. Drew, D., & Hewitt, H. (2006). A qualitative approach to understanding patients' diagnosis of Lyme disease. *Public Health Nursing*, *23*(1), 20-26.

20. Beck, S., Nakajima, R., Jasinskas, A., Abram, T. J., Kim, S. J., Bigdeli, N., ... & Zhao, W. (2022). A protein microarray-based respiratory viral antigen testing platform for COVID-19 surveillance. *Biomedicines*, *10*(9), 2238.

21. Jayaraman, V., Krishna, K., Yang, Y., Rajasekaran, K. J., Ou, Y., Wang, T., Bei, K., Krishnamurthy, H. K., Rajasekaran, J. J., Rai, A. J., & Green, D. A. (2020). An ultra-high-density protein microarray for high throughput single-tier serological detection of Lyme disease. *Scientific Reports*, *10*, 18085.

22. Grossberg, A. N., Koza, L. A., Ledreux, A., Prusmack, C., Krishnamurthy, H. K., Jayaraman, V., Granholm, A. C., & Linseman, D. A. (2021). A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients. *Nature communications*, *12*(740).

23. Tokarz, R., Mishra, N., Tagliafierro, T., Sameroff, S., Caciula, A., Chauhan, L., Patel, J., Sullivan, E., Gucwa, A., Fallon, B., Golightly, M., Molins, C., Schriefer, M., Marques, A., Briese, T., & Lipkin, W. I. (2018). A multiplex serologic platform for diagnosis of tick-borne diseases. *Sci Rep*, *8*(3158).

*24.* Rajasekaran, J. J., Jayaraman, V., Wang, T., Bei, K., Krishnamurthy, H, K. (2016). Methods, systems, and arrays for biomolecular analysis. *Patent No. 9417236B2*. United States.

25. Centers for Disease Control and Prevention. (2022, August 5). *Tickborne Diseases of the United States*. Centers for Disease Control and Prevention. Retrieved September 8, 2023.

26. Alhassan, A., Liu, H., McGill, J., Cerezo, A., Jakkula, L. U. M. R., Nair, A. D. S., Winkley, E., Olson, S., Marlow, D., Sahni, A., Narra, H. P., Sahni, S., Henningson, J., & Ganta, R. R. (2019). Rickettsia rickettsii Whole-Cell Antigens Offer Protection against Rocky Mountain Spotted Fever in the Canine Host. *Infection and immunity*, *87*(2), e00628-18.

27. Blanc, G., Ngwamidiba, M., Ogata, H., Fournier, P. E., Claverie, J. M., & Raoult, D. (2005). Molecular evolution of rickettsia surface antigens: evidence of positive selection. *Molecular biology and evolution*, *22*(10), 2073-2083.

28. Pornwiroon, W., Bourchookarn, A., Paddock, C. D., & Macaluso, K. R. (2009). Proteomic analysis of Rickettsia parkeri strain portsmouth. *Infection and immunity*, *77*(12), 5262–5271.

29. Kubelkova, K., & Macela, A. (2021). *Francisella* and Antibodies. *Microorganisms*, *9*(10), 2136.

30. Zhu, Y., Wu, Y., Chai, Y., Qi, J., Peng, R., Feng, W. H., & Gao, G. F. (2017). The Postfusion Structure of the Heartland Virus Gc Glycoprotein Supports Taxonomic Separation of the Bunyaviral Families Phenuiviridae and Hantaviridae. *Journal of virology*, *92*(1), e01558-17.

31. Marietta, E. V., Choung, R. S., Van Dyke, C. T., Brantner, T. L., Rajasekaran, J. J., Pasricha, P. J., Wang, T., Bei, K., Krishna, K., Krishnamurthy, H. K., Snyder, M. R., Jayaraman, V., & Murray, J. A. (2016). Determination of B-Cell Epitopes in Patients with Celiac Disease: Peptide Microarrays. *PLoS One*, *11*(1), e0147777.

32. Rostamkolaei, S. K., Choung, R. S., Ju, J. M., Marietta, E. V., Van Dyke, C. T., Rajasekaran, J. J., Jayaraman, V., Wang, T., Bei, K., Rajasekaran, K. E., Krishna, K., Krishnamurthy, H. K., & Murray, J. A. (2019). Synthetic Neoepitopes of the

Transglutaminase-Deamidated Gliadin Complex as Biomarkers for Diagnosing and Monitoring Celiac Disease. *Gastroenterology*, *156*(3), 582-591.e1.

33. Terry, W. D., & Fahey, J. L. (1964). SUBCLASSES OF HUMAN GAMMA-2-GLOBULIN BASED ON DIFFERENCES IN THE HEAVY POLYPEPTIDE CHAINS. *Science*, *146*(3642), 400-1.

34. Moore, A., Nelson, C., Molins, C., Mead, P., & Schriefer, M. (2016). Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of Lyme disease, United States. *Emerging infectious diseases*, *22*(7), 1169.

**35.** Ortiz, J. F., Millhouse, P. W., Cox, Á. M., Campoverde, L., Kaur, A., Wirth, M., & Atoot, A. (2020). Babesiosis: appreciating the pathophysiology and diverse sequela of the infection. *Cureus*, *12*(10).

36. Allizond, V., Costa, C., Sidoti, F., Scutera, S., Bianco, G., Sparti, R., ... & Musso, T. (2019). Serological and molecular detection of Bartonella henselae in specimens from patients with suspected cat scratch disease in Italy: A comparative study. *PloS one*, *14*(2), e0211945.

37. Reller, M. E., & Dumler, J. S. (2018). Development and clinical validation of a multiplex real-time quantitative PCR assay for human infection by Anaplasma phagocytophilum and Ehrlichia chaffeensis. *Tropical medicine and infectious disease*, *3*(1), 14.

38. Stewart, A. G., & Stewart, A. G. (2021). An update on the laboratory diagnosis of Rickettsia spp. infection. *Pathogens*, *10*(10), 1319.

39. Thomm, A. M., Schotthoefer, A. M., Dupuis, A. P., Kramer, L. D., Frost, H. M., Fritsche, T. R., ... & Kehl, S. C. (2018). Development and validation of a serologic test panel for detection of Powassan virus infection in US patients residing in regions where Lyme disease is endemic. *Msphere*, *3*(1), e00467-17.

40. Reusken, C., Boonstra, M., Rugebregt, S., Scherbeijn, S., Chandler, F., Avšič-Županc, T., ... & GeurtsvanKessel, C. H. (2019). An evaluation of serological methods to diagnose tick-borne encephalitis from serum and cerebrospinal fluid. *Journal of Clinical Virology*, *120*, 78-83.

41. Sambri, V., Capobianchi, M. R., Cavrini, F., Charrel, R., Donoso-Mantke, O., Escadafal, C., ... & Zeller, H. (2013). Diagnosis of west nile virus human infections: overview and proposal of diagnostic protocols considering the results of external quality assessment studies. *Viruses*, *5*(10), 2329-2348.

42. Bryant, P. A., Tingay, D., Dargaville, P. A., Starr, M., & Curtis, N. (2004). Neonatal coxsackie B virus infection—a treatable disease?. *European journal of pediatrics*, *163*, 223-228.

43. A Ross, S., Novak, Z., Pati, S., & B Boppana, S. (2011). Overview of the diagnosis of cytomegalovirus infection. *Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders)*, *11*(5), 466-474.

44. Jenson, H. B. (2004). Virologic diagnosis, viral monitoring, and treatment of Epstein-Barr virus infectious mononucleosis. *Current Infectious Disease Reports*, *6*, 200-207.

45. Manaresi, E., Gallinella, G., Zuffi, E., Bonvicini, F., Zerbini, M., & Musiani, M. (2002). Diagnosis and quantitative evaluation of parvovirus B19 infections by real time PCR in the clinical laboratory. *Journal of medical virology*, *67*(2), 275-281.

46. Souza, I. M. F. N. B. D., Siqueira, V. D. S., Ribeiro, I. D. C., Moraes, L. S. P., Prado,
D. P. G. D., Rezende, S. R., ... & Rezende, H. H. A. (2023). Molecular and
serological diagnosis of toxoplasmosis: a systematic review and meta-analysis.
*Revista do Instituto de Medicina Tropical de São Paulo*, *65*, e19.
47. Singh, A., Preiksaitis, J., & Romanowski, B. (2005). The laboratory diagnosis of
herpes simplex virus infections. *Canadian Journal of Infectious Diseases and Medical*
*Microbiology*, *16*(2), 92-98.
48. Norton, R. A., Caserta, M. T., Hall, C. B., Schnabel, K., Hocknell, P., & Dewhurst, S.
(1999). Detection of human herpesvirus 6 by reverse transcription-PCR. *Journal of*
*clinical microbiology*, *37*(11), 3672-3675.
49. Lipsett, S. C., Branda, J. A., & Nigrovica, L. E. (2019). Evaluation of the Modified
Two-Tiered Testing Method for Diagnosis of Lyme Disease in Children. *J Clin*
*Microbiol*, *57*(10), e00547-19.
50. Eisen, R. J., Kugeler, K. J., Eisen, L., Beard, C. B., & Paddock, C. D. (2017). Tick-
Borne Zoonoses in the United States: Persistent and Emerging Threats to Human
Health. *ILAR J*, *58*(3), 319–335.
51. Paddock CD, Lane RS, Staples JE, et al. (2016). CHANGING PARADIGMS FOR
TICK-BORNE DISEASES IN THE AMERICAS. In: Forum on Microbial Threats;
Board on Global Health; Health and Medicine Division; National Academies of
Sciences, Engineering, and Medicine. Global Health Impacts of Vector-Borne
Diseases: Workshop Summary. Washington (DC): National Academies Press (US).
52. Centers for Disease Control and Prevention. (2022, March 24). *Diseases Transmitted*
*by Ticks*. Centers for Disease Control and Prevention. Retrieved August 31, 2023.
53. Brown Marusiak, A., Hollingsworth, B. D., Abernathy, H., Alejo, A., Arahirwa, V.,
Mansour, O., Giandomenico, D., Schmitz, J., Williams, C., Barbarin, A. M., & Boyce,
R. M. (2022). Patterns Testing for Tick-Borne Diseases and Implications for
Surveillance in the Southeastern US. *JAMA network open*, *5*(5), e2212334.
54. Institute of Medicine (US) Committee on Lyme Disease and Other Tick-Borne
Diseases: The State of the Science. (2011). Diagnostics and Diagnosis. In *Critical*
*Needs and Gaps in Understanding Prevention, Amelioration, and Resolution of Lyme*
*and Other Tick-Borne Diseases: The Short-Term and Long-Term Outcomes:*
*Workshop Report*. National Academies Press (US).
55. Elnifro, E. M., Ashshi, A. M., Cooper, R. J., & Klapper, P. E. (2000). Multiplex PCR:
optimization and application in diagnostic virology. *Clin Microbiol Rev*, *13*(4), 559-
70.
56. Liu, H. Y., Hopping, G. C., Vaidyanathan, U., Ronquillo, Y. C., Hoopes, P. C., &
Moshirfar, M. (2019). Polymerase chain reaction and its application in the diagnosis
of infectious keratitis. *Medical Hypothesis, Discovery and Innovation in*
*Ophthalmology*, *8*(3), 152.
57. Leeflang, M. M., Ang, C. W., Berkhout, J., Bijlmer, H. A., Van Bortel, W.,
Brandenburg, A. H., Van Burgel, N. D., Van Dam, A. P., Dessau, R. B., Fingerle, V.,
Hovius, J. W., Jaulhac, B., Meijer, B., Van Pelt, W., Schellekens, J. F., Spijker, R.,
Stelma, F. F., Stanek, G., Verduyn-Lunel, F., Zeller, H., … Sprong, H. (2016). The
diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic
review and meta-analysis. *BMC infectious diseases*, *16*, 140.

58. Hilton, E., DeVoti, J., Benach, J. L., Halluska, M. L., White, D. J., Paxton, H., & Dumler, J. S. (1999). Seroprevalence and seroconversion for tick-borne diseases in a high-risk population in the northeast United States. *Am J Med*, *106*(4), 404-9.
59. Centers for Disease Control and Prevention (CDC). (1995). Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. *MMWR Morb Mortal Wkly Rep*, *44*(31), 590-1.
60. Aguero-Rosenfeld, M. E., Wang, G., Schwartz, I., & Wormser, G. P. (2005). Diagnosis of lyme borreliosis. *Clin Microbiol Rev*, *18*(3), 484-509.
61. Theel, E. S., Aguero-Rosenfeld, M. E., Pritt, B., Adem, P. V., & Wormser, G. P. (2019). Limitations and Confusing Aspects of Diagnostic Testing for Neurologic Lyme Disease in the United States. *J Clin Microbiol*, *57*(1), e01406-18.

**Table 1 Sample Cohort**

| Pathogen | N | Source (scientist/company) | Basis of Diagnosis |
|---|---|---|---|
| *Borrelia burgdorferi* | 298 | CDC, Private Clinics | RT-PCR, Physician |
| *Babesia microti* | 70 | Parasitology Laboratory, Wadsworth Center (NYSDOH) | RT-PCR, Blood Smear |
| *Babesia microti* | 118 | Seracare, Boca Bio, Private Clinics | Serology, RT-PCR |
| *Babesia microti* | 26 | Renata Welc-Falęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University) | Physician |
| *Bartonella henselae* | 119 | Private clinics | RT-PCR, Physician |
| *Bartonella henselae* | 26 | Renata Welc-Falęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University) | Physician |
| *Bartonella henselae* | 10 | Dimosthenis Chochlakis (University of Crete) | Physician |
| *Anaplasma phagocytophilum* | 118 | Private clinics, Boca Bio | RT-PCR, Serology |
| *Anaplasma phagocytophilum* | 26 | Renata Welc-Falęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University) | Physician |
| *Ehrlichia chaffeensis* | 120 | Private clinics, Boca Bio | RT-PCR, Serology |
| *Ehrlichia chaffeensis* | 26 | Renata Welc-Falęciak (University of Warsaw), Agnieszka Pawełczyk (Warsaw Medical University) | Physician |
| *Rickettsia typhi* | 70 | Lucas Blanton ( University of Texas Medical Branch) | Physician |
| *Rickettsia typhi* | 124 | Private clinics | RT-PCR, Physician |
| **Powassan virus** | 127 | Private clinics | RT-PCR, Physician |
| **Tick-borne encephalitis** | 111 | Daniel Rużek (Czech Academy of Sciences) | Physician |

| | | | |
|---|---|---|---|
| **Tick-borne encephalitis** | 124 | Private clinics | RT-PCR, Physician |
| **West Nile virus** | 20 | Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar) | Physician |
| **West Nile virus** | 124 | Private clinics | RT-PCR, Physician |
| **Coxsackie virus** | 45 | iSpecimen | Serology |
| **Coxsackie virus** | 124 | Private clinics | RT-PCR, Physician |
| **Cytomegalovirus** | 43 | DLS | Serology |
| **Cytomegalovirus** | 138 | Daniele Lilleri (Fondazione IRCCS Policlinico San Matteo) | Physician |
| **Cytomegalovirus** | 96 | Private Clinics | RT-PCR, Physician |
| **Cytomegalovirus** | 37 | Seracare | Serology |
| **Epstein Barr virus** | 20 | Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar) | Physician |
| **Epstein Barr virus** | 43 | Seracare | Serology |
| **Epstein Barr virus** | 14 | iSpecimen | Serology |
| **Epstein Barr virus** | 96 | Private clinics | RT-PCR, Physician |
| **Parvovirus B19** | 124 | Private clinics | RT-PCR, Physician |
| ***Toxoplasma gondii*** | 24 | Seracare | Serology |
| ***Toxoplasma gondii*** | 124 | Private clinics | RT-PCR, Physician |
| **HSV-1** | 20 | Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar) | Physician |
| **HSV-1** | 31 | Seracare | Serology |
| **HSV-1** | 96 | Private clinics | RT-PCR, Physician |
| **HSV-2** | 19 | Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar) | Physician |
| **HSV-2** | 27 | Seracare | Serology |
| **HSV-2** | 96 | Private clinics | RT-PCR, Physician |
| **HHV-6** | 20 | Gheyath K. Nasrallah (Weill Cornell Medicine-Qatar) | Physician |
| **HHV-6** | 96 | Private clinics | RT-PCR, Physician |

611   Table 1 provides an overview of the pathogens used in the study along with the total number

612   of samples, basis of diagnosis, and sample source.

614   **Table 2 Overview of pathogens and antigens**

| *Pathogen(Tick, if any)* | *Antigen* |
|---|---|
| *B. burgdorferi* (*I. scapularis*) | VlsE1, C6 peptide, DbpB, OspC, p28, p30, OspA, OspB, BmpA, p41, p45, p58, p66, p83-93, WCS B31, WCS 297. |

| | |
|---|---|
| *B. mayonii* (*I. scapularis*) | Whole cell sonicate |
| *B. afzelii* (*I. ricinus, I. persulatus*) | BmpA,DbpA,OspA,OspC,p100 |
| *B. garinii* (*I. ricinus, I. persulatus*) | DBpA,OspC |
| *B. bavariensis* (*I. uriae, I. persulcatus*) | p58,VLsE1, DbpA |
| *B. spielmanii* (*I. ricinus*) | DBpA,OspC |
| *B. hermsii* (*O. hermsi*) | Whole cell sonicate |
| *B. turicatae* (*O. turicatae*) | Whole cell sonicate |
| *B. miyamotoi* (*I. dentatus, I. ricinus, I. scapularis, I. pacificus*) | GlpQ |
| *B. andersonii* (*I. dentatus*) | Whole cell sonicate |
| *B. maritima* (*I. spinipalpis*) | Whole cell sonicate |
| *B. californiensis* (*I. jellisonii, I. spinipalpis, I. pacificus*) | Whole cell sonicate |
| *B. bissettiae* (*I.scapularis, I. persulatus, I. spinipalpis, I. pacificus*) | Whole cell sonicate |
| *B. lusitaniae* (*I. Ricinus*) | Whole cell sonicate |
| *B. valaisiana* (*I. ricinus, I. nippopensis, I. columnae*) | Whole cell sonicate |
| *B. yangtzensis* (*I. granulatus, I. nipponensis*) | Whole cell sonicate |
| *B. turcica* (*H. aegypticum*) | Whole cell sonicate |
| *Babesia microti* (*I. ricinus, I. scapularis*, blood transfusions, perinatal) | IRA, p32, p41, WCS |
| *Babesia duncani* (*I. ricinus, I. scapularis*, blood transfusions, perinatal) | Whole cell sonicate |
| *Bartonella henselae* | 17kDa, 26kDa, SucB |
| *Bartonella elizabethae* | Whole cell sonicate |
| *Bartonella vinsonii* | Whole cell sonicate |
| *Bartonella quintana* | Whole cell sonicate |
| *Anaplasma phagocytophilum* (*I. scapularis, I. ricinus*) | MSP5, MSP2, OmpA |
| *Ehrlichia chaffeensis* (*Amblyomma americanum*) | Whole cell sonicate |
| *Rickettsia typhi* (Flea *Xenopsylla cheopis, Ctenocephalides felis*) | Omp B, surface antigen |
| Powassan virus (*Hemaphysalis longicornis, I. scapularis, I.cookei*) | Whole cell sonicate |
| Tick-borne encephalitis virus (*I. ricinus, I. persulcatus*) | Whole cell sonicate |
| West Nile virus (*I. ricinus, O. moubata*) | Whole cell sonicate |
| Coxsackie virus (*Amblyomma americanum*) | Whole cell sonicate |
| Cytomegalovirus | EIA, gB,p150,p28,p52,pp65,p38 |
| Epstein Barr virus | EA, EBNA1, VCA gp125,p18, p23 |
| Parvovirus B19 | VLP VLP2,VLP VP1/VP2 Co Capsid |
| *Toxoplasma gondii* (Multiple Ticks) | WCS, MIC3,p24,p29,p30 |

| HSV-1 | Whole cell sonicate |
|---|---|
| HSV-2 | Whole cell sonicate |
| HHV-6 | Whole cell sonicate |

615     Table 2 consists of all the pathogens and their respective antigens.

616     **Table 3 Antigen sensitivities**

| Pathogen | IgM | | IgG | | IgM+IgG | | Gold Std [34-48] | |
|---|---|---|---|---|---|---|---|---|
| | Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity |
| | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| *Borrelia burgdorferi* | 60 | 100 | 94 | 100 | 100 | 100 | Early: 30-40 Late: 70-100 | 95-100 |
| *Babesia microti* | 79 | 98 | 91 | 97 | 99 | 96 | 70-80 | 94-100 |
| *Bartonella henselae* | 81 | 99 | 96 | 99 | 100 | 98 | 100 | 96.8 |
| *Anaplasma phagocytophilum* | 94 | 100 | 100 | 100 | 100 | 100 | 80-100 | 95-100 |
| *Ehrlichia chaffeensis* | 84 | 100 | 100 | 99 | 100 | 99 | 83 | 100 |
| *Rickettsia typhi* | 86 | 100 | 83 | 100 | 97 | 100 | 80-100 | 91-100 |
| **Powassan virus** | 100 | 100 | 100 | 100 | 100 | 100 | 89 | 35-84 |
| **Tickborne encephalitis** | 78 | 99 | 92 | 99 | 93 | 98 | 94-100 | >95 |
| **West Nile virus** | 25 | 100 | 80 | 100 | 85 | 100 | 80-95 | 94-100 |
| **Coxsackie virus** | 56 | 100 | 100 | 100 | 100 | 100 | 94-97 | 100 |
| **Cytomegalovirus** | 100 | 100 | 100 | 100 | 100 | 100 | 89.2 | 95 |
| **Epstein Barr virus VCA** | 100 | 100 | 96 | 100 | 97 | 100 | 80-95 | >95 |
| **Epstein Barr virus EBNA1** | 95 | 100 | 96 | 100 | 97 | 100 | 80-95 | >95 |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Parvovirus B19** | 90 | 99 | 98 | 98 | 99 | 97 | >90 | >90 |
| *Toxoplasma gondii* | 100 | 99 | 100 | 100 | 100 | 99 | >90 | >95 |
| **HSV-1** | 100 | 100 | 98 | 100 | 98 | 100 | 97-100 | 98 |
| **HSV-2** | 100 | 100 | 98 | 100 | 98 | 100 | 97-100 | 98 |
| **HHV-6** | 95 | 100 | 95 | 100 | 95 | 100 | >95 | >95 |

618  Table 3 shows the IgG, IgM, and IgG+IgM sensitivities and specificities obtained using the

619  Vibrant microarray and a comparison with the sensitivities and specificities of the current

620  gold standard for respective pathogens.

622  **Table 4 Individual antigen sensitivities (*B. burgdorferi)***

| Antigen | IgM | IgG |
|---|---|---|
| *VlsE1* | 61% | 91% |
| *C6* | 39% | 60% |
| *B31* | 37% | 48% |
| *B297* | 36% | 57% |
| *p18* | 6% | 41% |
| *p23* | 47% | 68% |
| *p28* | 4% | 28% |
| *p30* | 5% | 35% |
| *p31* | 17% | 38% |
| *p34* | 16% | 41% |
| *p39* | 29% | 66% |
| *p41* | 34% | 53% |
| *p45* | 5% | 35% |
| *p58* | 5% | 35% |
| *p66* | 7% | 39% |
| *p93* | 32% | 60% |

624  Table 4 shows the IgG and IgM values for the individual antigens of *Borrelia burgdorferi*

Figure 1: Wafer Processing, Antigen Immobilisation, Pillar Plate Assembly. A poly (lactic acid) and poly (L-lysine) copolymer solution is coated onto the silicon wafers and further immobilized with protein probes [steps 1-3]. The wafers are then diced into microchips using a stealth dicing process [step 4]. A standard die sorting system is used to pick and place the microchips onto carrier plates [step 5]. The carrier tapes are loaded onto a high throughput surface mount technology (SMT) component placement system and individual microchips are placed onto 24-pillar plates. Each pillar consists of 87 microchips [step 6].

Figure 2: Overview of all the pathogens and their respective antigens used in the study.

Figure 3: Heat map showing Lyme disease antigen reactivity. The positivity cutoff for each antigen was set at greater than 10 chemiluminescent units (CU) (shown as yellow or red).  The color key is as follows: Red - High positive (CU>20); Yellow, orange - Moderate positive (CU = 10.1-20); White - Negative (CU≤10).